Ivermectin In Treatment of COVID 19 Patients

The Use of Ivermectin In the Treatment of COVID 19 Patients

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04425707

Enrollment

100

Registered

2020-06-11

Start date

2020-06-09

Completion date

2020-09-01

Last updated

2020-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Brief summary

as Egypt suffered a lot during the pandemic of COVID 19 with limited drug choices, many of the patients could not acheive viral clearence with the standard module of care teh idea of introduction of new medications in the treatment protocol of COVID 19 managment. Ivermectin had shown a promising results in vitro studies and in limited in vivo studies. this clinical trial may open a new hope for COVID 19 patients as a new and cheap line of treatment

Detailed description

the study will compare the effect of ivermectin in comaprison and addition to the standard mode of care for the COVID 19 patients

Interventions

DRUGIvermectin

use of Ivermectin in the treatment of COVID 19 patients, in comparison to and in addition to the standard care of treatment of COVID 19 in Egypt

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Asymptomatic mild cases and moderate cases proven to be infected by COVID 19 by viral RNA swap

Exclusion criteria

* Contraindications for the drug: hypersensitivity. * Any medications with possible drug interactions. * Severe cases. * Any malignant condition. * Pregnant females. * Breast feeding females. * Any patient on the following medications: Erdafitinib- Lasmiditan- Quinidine due to potential severe drug interaction.

Design outcomes

Primary

Measure	Time frame	Description
to evaluate the role of Ivermectin as a line of treatment for COVID 19	2 months	the role of ivermectin in the cure of COVID 19 patients

Secondary

Measure	Time frame	Description
To asses the rate of viral clearance in comparison to other treatment protocols.	2 months	to compare the results of ivermectin with the standard care

Countries

Egypt

Contacts

Primary Contactehab ah kamal, MD

ehabkamal2011@hotmail.com01006162663

Backup Contactnoha mo asem, MD

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026